{% extends "layout.html" %}
  
{% block title %}Proposed Implementation{% endblock %}

{% block img0url %}https://static.igem.wiki/teams/4190/wiki/banner-gif/ezgif-1-bfff312da7.gif{% endblock %}
{% block img0desc %}{% endblock %}

{% block header %}

    <div class="carousel-inner">
      <div class="carousel-item active">
        <img src="{{ self.img0url() }}" class="d-block" alt="{{ self.img0desc() }}">
        <div class="carousel-caption">
          <h1>{{ self.title() }}</h1>
          <h4>{{ self.img0desc() }}</h4>
        </div>
      </div>
    </div>

{% endblock %}
{% block sideBarEntries %}

  <a class="nav-link active" aria-current="page" href="#implementation1">Making <i>S. cerevisiae</i> a Final Host for Oral Drug Delivery</a>
  <a class="nav-link" href="#implementation2">Other Modes of Bioencapsulation</a>
  <a class="nav-link" href="#implementation3">Drug Dosage</a>
  <a class="nav-link" href="#implementation4">Ethics and Safety</a>
  <a class="nav-link" href="#Citation-Accordion">Citations</a>

{% endblock %}
{% block page_content %}
    
    <h4 id="implementation1" class="sectionHead"><strong>Making <i>S. cerevisiae</i> a Final Host for Oral Drug Delivery</strong></h4>
    <div class="bodyParagraph">
      <p><a class="glossaryRef" title="T2D" href="https://2022.igem.wiki/ucsc/glossary#T2D">T2D</a> patients inject themselves with medication three to four times a day and prick their skin to measure blood glucose an additional three to four times a day [<a class="citation" href="#Citation-Accordion">1</a>]. Subcutaneous administration of T2D medications host a variety of issues including needle supply, needle sterility, and bloodborne pathogens such as hepatitis B, hepatitis C, and HIV [<a class="citation" href="#Citation-Accordion">2</a>]. Unsafe injections are more prevalent in resource constrained communities, making this an especially pressing issue to address given such countries are disproportionately impacted by T2D [<a class="citation" href="#Citation-Accordion">3</a>]. <strong>We decided to reduce these potential hazards by eliminating needles and pursuing Helo as an orally deliverable T2D medication</strong>. </p>
      <p>For <a class="glossaryRef" title="S_cerevisiae" href="https://2022.igem.wiki/ucsc/glossary#S_cerevisiae"><i>S. cerevisiae</i></a> to become an accessible and novel <a class="glossaryRef" title="Eukaryote" href="https://2022.igem.wiki/ucsc/glossary#Eukaryote">eukaryotic</a> host for oral drug delivery, we must first modify its <a class="glossaryRef" title="Surface-Proteins" href="https://2022.igem.wiki/ucsc/glossary#Surface-Proteins">surface proteins</a> [<a class="citation" href="#Citation-Accordion">4</a>]. Surface protein modification transforms <i>S. cerevisiae</i> cells into accurate therapeutic carriers, enhancing drug delivery efficiency [<a class="citation" href="#Citation-Accordion">5</a>]. By reinforcing <i>S. cerevisiae's</i> cell wall, otherwise known as <a class="glossaryRef" title="Bioencapsulation" href="https://2022.igem.wiki/ucsc/glossary#Bioencapsulation">bioencapsulation</a>, we hypothesize Ex-4 will be able to bypass the  <a class="glossaryRef" title="Gastrointestinal-Barrier" href="https://2022.igem.wiki/ucsc/glossary#Gastrointestinal-Barrier">gastrointestinal barrier</a> and target epithelial <a class="glossaryRef" title="M-Cell" href="https://2022.igem.wiki/ucsc/glossary#M-Cell">M cells</a> for final drug release. We plan to test various surface protein modifications to determine the ideal edit for our desired dosage.</p>
      <p>To further implement our system, we plan to replace our galactose <a class="glossaryRef" title="Promoter" href="https://2022.igem.wiki/ucsc/glossary#Promoter">promoter</a> for Ex-4 with an alternative lactose promoter (LAC9) [<a class="citation" href="#Citation-Accordion">6</a>]. As lactose is abundant in milk [<a class="citation" href="#Citation-Accordion">7</a>], it is it is an optimal Ex-4 protein expression inducer that is economical and widely accessible with over six billion people consuming milk globally [<a class="citation" href="#Citation-Accordion">8</a>]. Due to our genomic insert's current design, our yeast would only be able to produce Ex-4 in milk that contains lactase; the enzyme which breaks down lactose into glucose and galactose. This enzyme can be bought under the brand LACTAID® but adds an additional cost and assumes LACTAID® is accessible by our target users. <strong>By replacing our GAL1 promoter with a LAC9 promoter, we hypothesize our <i>S. cerevisiae</i> will express Ex-4 in milk, meaning global communities will be able to continuously produce their own T2D medication locally. Further, the genomic integration of Ex-4 in <i>S. cerevisiae</i> implies stable propagation of the protein for generations</strong>. </p>
    <p>Lastly, an elastin-based polypeptide  <a class="glossaryRef" title="half-life" href="https://2022.igem.wiki/ucsc/glossary#half-life">half-life</a> extender sequence was added to our insert on the C-terminus of the <i>S. cerevisiae</i> gene fragment. The half-life extender is made up of a ten times repeat of the VPGVG amino acid sequence, and has been shown to increase the half-life of Ex-4 by 3.7 fold [<a class="citation" href="#Citation-Accordion">9</a>]. We will utilize this component once we reach <a class="glossaryRef" title="in-vivo" href="https://2022.igem.wiki/ucsc/glossary#in-vivo"><i>in vivo</i></a> trials. The optimized codon sequence will produce our functional protein when translated, and the half-life extender should not interfere with the binding between Ex-4 and the <a class="glossaryRef" title="Exendin-4" href="https://2022.igem.wiki/ucsc/glossary#GLP-1-R">GLP-1 R</a>.</p>
    </div>
    <br>
    
    <h4 id="implementation2" class="sectionHead"><strong>Other Modes of Bioencapsulation</strong></h4>
    <div class="bodyParagraph">
      <p>In the event that reinforcing the cell wall of <i>S. cerevisiae</i> does not result in effective bioencapsulation, we considered Ex-4 expression in plant and algal hosts. Both plant and algal cell walls act as bioencapsulation mechanisms to protect protein drugs for oral delivery [<a class="citation" href="#Citation-Accordion">10</a>]. Additionally, recombinant chloroplasts yield high levels of protein expression and proper folding [<a class="citation" href="#Citation-Accordion">11</a>][<a class="citation" href="#Citation-Accordion">12</a>][<a class="citation" href="#Citation-Accordion">13</a>]. We also considered soybeans for their low <a class="glossaryRef" title="Glycemic-Index" href="https://2022.igem.wiki/ucsc/glossary#Glycemic-Index">glycemic index</a> of 4.5, bioencapsulation ability, history of <a class="glossaryRef" title="Transformation" href="https://2022.igem.wiki/ucsc/glossary#Transformation">transformation</a>, and well documented genome [<a class="citation" href="#Citation-Accordion">14</a>].</p>
      <p>Furthermore, we looked into the algae, <i>Chlamydomonas reinhardtii</i> (<i>C. reinhardtii</i>), as a potential host. <i>C. reinhardtii</i> is known as a photosynthetic yeast due to its rapid growth and high photosynthetic efficiency [<a class="citation" href="#Citation-Accordion">15</a>]. Recombinant therapeutic proteins have been successfully expressed within chloroplasts and are therefore worth investigating for Ex-4 production [<a class="citation" href="#Citation-Accordion">16</a>]. Exploring alternative hosts will allow us to compare <a class="glossaryRef" title="Bioavailability" href="https://2022.igem.wiki/ucsc/glossary#Bioavailability">bioavailability</a> and protein production, as well as give us a holistic understanding of potential delivery systems to increase Ex-4 accessibility.</p>
    </div>
    <br>

    <h4 id="implementation3" class="sectionHead"><strong>Drug Dosage</strong></h4>
    <div class="bodyParagraph">
      <p>After meeting with several endocrinologists, we discovered Ex-4 functions exclusively in the presence of elevated blood glucose, meaning that Ex-4 induced hypoglycemia is highly unlikely [<a class="citation" href="#Citation-Accordion">17</a>]. However, understanding the limits of our dosage remains an important component to the safe implementation of Helo. To ascertain what dose of Ex-4 we want <i>S. cerevisiae</i> to produce, our team coded a <a href="{{ url_for('pages', page='model') }}">dosage-effect model</a>. This model shows the correlation between a given dosage of Ex-4 and its pharmacological effect: insulin production within pancreatic <a class="glossaryRef" title="Beta-Cell" href="https://2022.igem.wiki/ucsc/glossary#Beta-Cell">beta cells</a>. The formula used to model this effect falls under the umbrella of <a class="glossaryRef" title="Pharmacodynamics" href="https://2022.igem.wiki/ucsc/glossary#Pharmacodynamics">pharmacodynamic</a>. We will collect data for this model by incubating recombinant Ex-4 produced by <i>S. cerevisiae</i> and <a class="glossaryRef" title="E_coli" href="https://2022.igem.wiki/ucsc/glossary#E_coli"><i>E. coli</i></a> with pancreatic mice cells. If Ex-4 binds to the <a class="glossaryRef" title="GLP-1-R" href="https://2022.igem.wiki/ucsc/glossary#GLP-1-R">GLP-1 R</a> on those cells, we expect to see an influx of insulin secretion as measured by an Enzyme-Linked ImmunoSorbent Assay (<a class="glossaryRef" title="ELISA" href="https://2022.igem.wiki/ucsc/glossary#ELISA">ELISA</a>).</p>
    </div>
    <br>
    <h4 id="implementation4" class="sectionHead"><strong>Ethics and Safety</strong></h4>
    <div class="bodyParagraph">
      <p><strong>A large aspect of our project was ensuring integration of our Ex-4 gene cassette into a safe and edible organism.</strong> <i>S. cerevisiae</i> is Generally Recognized as Safe (<a class="glossaryRef" title="GRAS" href="https://2022.igem.wiki/ucsc/glossary#GRAS">GRAS</a>) by the U.S. <a class="glossaryRef" title="FDA" href="https://2022.igem.wiki/ucsc/glossary#FDA">FDA</a> [<a class="citation" href="#Citation-Accordion">18</a>] and is commonly referred to as baker's yeast.</p>
      <p>Cold chain storage describes the system of transporting and storing medications in refrigerated vehicles when en route to pharmacies. This system limits access to medication for many resource constrained communities. <strong> method of bypassing cold chain storage for our product would be to distribute our recombinant <i>S. cerevisiae</i> cultures as Active Dry Yeast (ADY).</strong> ADY has a shelf-life of around 12 to 18 months and does not require refrigerated storage [<a class="citation" href="#Citation-Accordion">19</a>]. Since Ex-4 is a heat stable protein at room temperature [<a class="citation" href="#Citation-Accordion">20</a>], we hypothesize that it could be contained within our dried yeast without experiencing denaturation.</p>
      <p>By mixing our ADY with sugar and warm water, T2D patients can grow an <i>S. cerevisiae</i> starter culture. After the ADY is rehydrated, it can be stored in a refrigerator for up to two weeks [<a class="citation" href="#Citation-Accordion">21</a>]. <i>S. cerevisiae</i> can grow in the presence of sucrose or maltose [<a class="citation" href="#Citation-Accordion">22</a>] [<a class="citation" href="#Citation-Accordion">23</a>], two sugars that are abundantly present in most places around the world. For sucrose based growth media, communities can use water mixed with sugarcane, honey, maple syrup, sugar beets, molasses, agave, dates, and other fresh or canned fruits [<a class="citation" href="#Citation-Accordion">24</a>] to support culture growth. <strong> This culture may then be induced with milk to express Ex-4 via the LAC9 promoter we plan to implement within our system. We theorize that Ex-4 may be stored and propagated at local pharmacies and communities in less than one square meter.</strong></p>
      <p>Further, we plan to explore other strains of yeast such as <i>Yarrowia lipolytica</i> and <i>Pichia pastoris</i> as potential Ex-4 hosts given their low maintenance care, diverse set of growing conditions, and GRAS status [<a class="citation" href="#Citation-Accordion">25</a>][<a class="citation" href="#Citation-Accordion">26</a>]. Our newly established background in yeast engineering will allow us to test and choose the best Ex-4 producing strain of yeast. In addition, it is imperative the system we create prioritizes accessibility, low-cost, and safety. Our system will not be brought to market until we are confident that Helo is effective and safe to consume as confirmed by governmental bodies such as the U.S. FDA. We will perform a western blot analysis, <a class="glossaryRef" title="Binding-Affinity" href="https://2022.igem.wiki/ucsc/glossary#Binding-Affinity">binding affinity</a> assay, and <i>in vitro</i> pancreatic mice cell culture test as steps to confirm the functionality and safety of our recombinant Ex-4.</p>
      <p>Helo will be considered a genetically modified organism (GMO), which is a label that comes with many controversial aspects. However, Ex-4 is approved by the U.S. FDA and is currently marketed for subcutaneous injection [<a class="citation" href="#Citation-Accordion">27<a>]. We aim to show that using living systems to produce protein drugs is a cheaper and more accessible alternative to traditional drug manufacturing. <strong>Our locally grown system will be independent from large pharmaceutical companies while still maintaining efficacy and safety. Hence, we hope to reduce the stigmas associated with GMOs while simultaneously providing more accessible treatment for T2D patients.</strong></p>
    </div>

<br>
 <div class="accordion bg-dark my-5" id="Citation-Accordion">
    <div class="accordion-item">
      <h2 class="accordion-header" id="Citation-AccordionHeading1">
        <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapseCitations" aria-expanded="false" aria-controls="collapseCitations">
          Citations
        </button>
      </h2>
      <div id="collapseCitations" class="accordion-collapse collapse" aria-labelledby="Citation-AccordionHeading1" data-bs-parent="#Citation-Accordion">
        <div class="accordion-body">
          <ol class="noBP">
            <li id="citation1">[1] "Insulin Routines |ADA" <a class="citation" href="https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-routines">https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-routines</a> (accessed Oct. 11, 2022)</li>
            <li id="citation2">[2] L. Simonsen, A. Kane, J. Lloyd, M. Zaffran, and M. Kane, “Unsafe injections in the developing world and transmission of bloodborne pathogens: a review,” <i>Bull World Health Organ</i>, vol. 77, no. 10, pp. 789–800, 1999.</li>
            <li id="citation3">[3] “Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025 | Scientific Reports.” <a class="citation" href=" https://www.nature.com/articles/s41598-020-71908-9">https://www.nature.com/articles/s41598-020-71908-9</a></li>
            <li id="citation4">[4] C. Sabu, P. Mufeedha, and K. Pramod, “Yeast-inspired drug delivery: biotechnology meets bioengineering and synthetic biology,” <i> Opinion on Drug Delivery</i>, vol. 16, no. 1, pp. 27–41, Jan. 2019, doi: <a class="citation" href="https://doi.org/10.1080/17425247.2019.1551874">https://doi.org/10.1080/17425247.2019.1551874</a>.</li>
              <li id="citation5">[5] E. E. Kenngott et al., “Surface-modified yeast cells: A novel eukaryotic carrier for oral application,” <i>Journal of Controlled Release</i>, vol. 224, pp. 1–7, Feb. 2016, <a class="citation" href="https://doi.org/10.1016/j.jconrel.2015.12.054">https://doi.org/10.1016/j.jconrel.2015.12.054</a>.</li>
              <li id="citation6">[6] K. D. Breunig, “Glucose repression of LAC gene expression in yeast is mediated by the transcriptional activator LAC9,”<i> Mol Gen Genet</i>, vol. 216, no. 2, pp. 422–427, Apr. 1989,<a class="citation" href="https://doi.org/10.1007/BF00334386">https://doi.org/10.1007/BF00334386</a>.</li>
              <li id="citation7">[7] G. Schaafsma, “Lactose and lactose derivatives as bioactive ingredients in human nutrition,” <i>International Dairy Journal</i>, vol. 18, no. 5, pp. 458–465, May 2008, <a class="citation" href="https://doi.org/10.1016/j.idairyj.2007.11.013">https://doi.org/10.1016/j.idairyj.2007.11.013</a>.</li>
              <li id="citation8">[8] “Dairy production and products: Products.” <a class="citation" href="https://www.fao.org/dairy-production-products/products/en/">https://www.fao.org/dairy-production-products/products/en/</a>.</li>
              <li id="citation9">[9] S. J. Jung et al., “In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae,” <i>J Biotechnol</i>, vol. 303, pp. 16–24, Sep. 2019, <a class="citation" href="https://doi.org/10.1016/j.jbiotec.2019.06.304">https://doi.org/10.1016/j.jbiotec.2019.06.304</a>.</li>
              <li id="citation10">[10] T. Ruhlman, R. Ahangari, A. Devine, M. Samsam, and H. Daniell, “Expression of cholera toxin B–proinsulin fusion protein in lettuce and tobacco chloroplasts – oral administration protects against development of insulitis in non-obese diabetic mice,” <i>Plant Biotechnol J</i>, vol. 5, no. 4, pp. 495–510, Jul. 2007, <a class="citation" href="https://doi.org/10.1111/j.1467-7652.2007.00259.x">https://doi.org/10.1111/j.1467-7652.2007.00259.x</a>.</li>
              <li id="citation11">[11] D. Boyhan and H. Daniell, “Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide,” <i>Plant Biotechnol J</i>, vol. 9, no. 5, pp. 585–598, Jun. 2011, <a class="citation" href="https://doi.org/10.1111/j.1467-7652.2010.00582.x">https://doi.org/10.1111/j.1467-7652.2010.00582.x</a>.</li>
              <li id="citation12">[12] H. Daniell, N. D. Singh, H. Mason, and S. J. Streatfield, “Plant-made vaccine antigens and biopharmaceuticals,” <i>Trends Plant Sci</i>, vol. 14, no. 12, pp. 669–679, Dec. 2009, <a class="citation" href="https://doi.org/10.1016/j.tplants.2009.09.009">https://doi.org/10.1016/j.tplants.2009.09.009</a>.</li>
              <li id="citation13">[13] K.-C. Kwon, R. Nityanandam, J. S. New, and H. Daniell, “Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells,” <i>Plant Biotechnol J</i>, vol. 11, no. 1, pp. 77–86, Jan. 2013, <a class="citation" href="https://doi.org/10.1111/pbi.12008">https://doi.org/10.1111/pbi.12008</a>.</li>
              <li id="citation14">[14] admin, “Soybean: Glycemic Index (GI), glycemic load (GL) and calories per 100g,” <i>Glycemic Index (GI) & Glycemic Load (GL) Guide</i>, Feb. 08, 2021.<a class="citation" href="https://glycemic-index.net/soybean/">https://glycemic-index.net/soybean/</a>.</li>
              <li id="citation15">[15] J.-D. Rochaix, “Chlamydomonas reinhardtii as the photosynthetic yeast,” <i>Annual Review of Genetics</i>, vol. 29, pp. 209–231, Jan. 1995.</li>
              <li id="citation16">[16] E. A. Cutolo, G. Mandalà, L. Dall’Osto, and R. Bassi, “Harnessing the Algal Chloroplast for Heterologous Protein Production,” <i>Microorganisms</i>, vol. 10, no. 4, Art. no. 4, Apr. 2022, <a class="citation" href="https://doi.org/10.3390/microorganisms10040743">https://doi.org/10.3390/microorganisms10040743</a>.</li>
              <li id="citation17">[17] D. D. De León, C. Li, M. I. Delson, F. M. Matschinsky, C. A. Stanley, and D. A. Stoffers, “Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion,” <i>J Biol Chem</i>, vol. 283, no. 38, pp. 25786–25793, Sep. 2008, <a class="citation" href="https://doi.org/10.1074/jbc.M804372200">https://doi.org/10.1074/jbc.M804372200</a>.</li>
              <li id="citation18">[18] V. Sewalt, D. Shanahan, L. Gregg, J. La Marta, and R. Carrillo, “The Generally Recognized as Safe (GRAS) Process for Industrial Microbial Enzymes,” <i>Industrial Biotechnology</i>, vol. 12, no. 5, pp. 295–302, Oct. 2016, <a class="citation" href="https://doi.org/10.1089/ind.2016.0011">https://doi.org/10.1089/ind.2016.0011</a>.</li>
              <li id="citation19">[19] “Yeast 101 | Fleischmann’s®,” fly-local. <a class="citation" href="https://www.fleischmannsyeast.com/baking-basics/yeast-101/">https://www.fleischmannsyeast.com/baking-basics/yeast-101/</a>.</li>
              <li id="citation20">[20] “Exendin 4 Protein Human Recombinant Hormone | ProSpec,” <i>prospecbio</i>. <a class="citation" href="https://www.prospecbio.com/exendin-4">https://www.prospecbio.com/exendin-4</a>.</li>
              <li id="citation21">[21] “Preserving yeast cultures - OpenWetWare.”<a class="citation" href="https://openwetware.org/wiki/Preserving_yeast_cultures">https://openwetware.org/wiki/Preserving_yeast_cultures</a>.</li>
              <li id="citation22">[22] “Sucrose and <i>Saccharomyces cerevisiae</i>: a relationship most sweet | FEMS Yeast Research | Oxford Academic.” <a class="citation" href="https://academic.oup.com/femsyr/article/16/1/fov107/2467713">https://academic.oup.com/femsyr/article/16/1/fov107/2467713</a> (accessed Oct. 11, 2022).</li>
              <li id="citation23">[23] M. L. A. Jansen, P. Daran-Lapujade, J. H. de Winde, M. D. W. Piper, and J. T. Pronk, “Prolonged Maltose-Limited Cultivation of <i>Saccharomyces cerevisiae</i> Selects for Cells with Improved Maltose Affinity and Hypersensitivity,” Appl Environ Microbiol, vol. 70, no. 4, pp. 1956–1963, Apr. 2004, doi: <a class="citation" href="https://journals.asm.org/doi/10.1128/AEM.70.4.1956-1963.2004">10.1128/AEM.70.4.1956-1963.2004.</a></li>
              <li id="citation24">[24] “Sources of Sugar - The Canadian Sugar Institute.” <a class="citation" href="https://sugar.ca/sugar-basics/sources-of-sugar">https://sugar.ca/sugar-basics/sources-of-sugar</a> (accessed Oct. 11, 2022).</li>
              <li id="citation25">[25] B. Zieniuk and A. Fabiszewska, “Yarrowia lipolytica: a beneficious yeast in biotechnology as a rare opportunistic fungal pathogen: a minireview,” World J Microbiol Biotechnol, vol. 35, no. 1, p. 10, 2019, doi: <a class="citation" href="https://link.springer.com/article/10.1007/s11274-018-2583-8">10.1007/s11274-018-2583-8</a>.</li>
              <li id="citation26">[26] “Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins - PMC.” <a class="citation" href="https://onlinelibrary.wiley.com/doi/10.1002/jcp.29583">https://onlinelibrary.wiley.com/doi/10.1002/jcp.29583</a> (accessed Oct. 11, 2022).</li>
              <li id="citation27">[27] “Drug Approval Package: Byetta (Exenatide) NDA #021773,” www.accessdata.fda.gov. 
<a class="citation" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_byettatoc.cfm">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_byettatoc.cfm</a></li>

          </ol>
        </div>
      </div>
    </div>
  </div>
<br>

{% endblock %}
